American Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical’s Clinical Research at 2025 Annual Meeting

Mar 10, 2025 | Press Releases

Interim Results from clinical study for cutaneous carcinomas presented at Late-Breaking Research SessionMarlborough, Massachusetts–(Newsfile Corp. – March 10, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company...

Phio Pharmaceuticals Announces Completion of Enrollment in Third Safety Cohort in PH-762 Phase 1b Dose-Escalation Study

Mar 5, 2025 | Press Releases

Marlborough, Massachusetts–(Newsfile Corp. – March 5, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silencing technology designed to make the...

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Feb 26, 2025 | Press Releases

Registration Link for Presentation and live Q&A to take place, Wednesday March 5, 2025 at 12:00 pm ESTMarlborough, Massachusetts–(Newsfile Corp. – February 26, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) a clinical-stage biotechnology...

Phio Pharmaceuticals Announces Appointment of David H. Deming to Board of Directors

Feb 20, 2025 | Press Releases

Marlborough, Massachusetts–(Newsfile Corp. – February 20, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silencing technology designed to make...

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Feb 3, 2025 | Press Releases

Registration Link for Presentation and live Q&A to take place, Tuesday February 4, 2025 at 2:00 pm ESTMarlborough, Massachusetts–(Newsfile Corp. – February 3, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology...